Search

everythinglearnresearchcommunity

for

Search:↓

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user is concerned about mixing Pantostin (with Alfatradiol) and Finasteride in a topical solution, fearing a potential toxic reaction or ineffectiveness. They seek advice on whether this combination is safe.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

User seeks Procyanidin B2 supplement source and asks for dosage comparison. Another user requests study details and apple type importance.

The conversation discusses using shou wu chih or fo-ti/he shou wu for hair loss, with OP noticing stiffer beard and body hair. A user warns about potential liver damage from fo-ti and questions the effectiveness of alternative medicine.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, RU58841, and Sulforaphane supplements. Two brands of Sulforaphane supplements, Avmacol and Prostaphane, are mentioned with optimal dosages.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

User started using Pantostin Alfatradiol after watching haircafe on YouTube and noticed thicker hair. They wonder why it's not more popular, as it's a 5α-reductase inhibitor with a different mechanism than minoxidil.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.

Finasteride significantly lowers allopregnanolone levels, while dutasteride's effect is less clear and may vary. Some users speculate that dutasteride might be healthier for the brain due to its different inhibition pathways.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.